[go: up one dir, main page]

EE05548B1 - Kasvaja nekroosifaktori sarnase apoptoosi indutseeriva ligandi retseptori suhtes selektiivne antikeha ja selle kasutamine - Google Patents

Kasvaja nekroosifaktori sarnase apoptoosi indutseeriva ligandi retseptori suhtes selektiivne antikeha ja selle kasutamine

Info

Publication number
EE05548B1
EE05548B1 EEP200200621A EEP200200621A EE05548B1 EE 05548 B1 EE05548 B1 EE 05548B1 EE P200200621 A EEP200200621 A EE P200200621A EE P200200621 A EEP200200621 A EE P200200621A EE 05548 B1 EE05548 B1 EE 05548B1
Authority
EE
Estonia
Prior art keywords
apoptosis
necrosis factor
tumor necrosis
ligand receptor
inducing ligand
Prior art date
Application number
EEP200200621A
Other languages
English (en)
Inventor
Zhou Tong
Ichikawa Kimihisa
P. Kimberly Robert
J. Koopman William
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of EE200200621A publication Critical patent/EE200200621A/et
Publication of EE05548B1 publication Critical patent/EE05548B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
EEP200200621A 2000-05-02 2001-05-02 Kasvaja nekroosifaktori sarnase apoptoosi indutseeriva ligandi retseptori suhtes selektiivne antikeha ja selle kasutamine EE05548B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20134400P 2000-05-02 2000-05-02
PCT/US2001/014151 WO2001083560A1 (en) 2000-05-02 2001-05-02 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Publications (2)

Publication Number Publication Date
EE200200621A EE200200621A (et) 2004-06-15
EE05548B1 true EE05548B1 (et) 2012-06-15

Family

ID=22745456

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200621A EE05548B1 (et) 2000-05-02 2001-05-02 Kasvaja nekroosifaktori sarnase apoptoosi indutseeriva ligandi retseptori suhtes selektiivne antikeha ja selle kasutamine

Country Status (27)

Country Link
US (6) US7244429B2 (et)
EP (4) EP2065401B1 (et)
JP (4) JP4156238B2 (et)
KR (2) KR20060092292A (et)
CN (2) CN101585881B (et)
AT (1) ATE426615T1 (et)
AU (2) AU5936601A (et)
BG (3) BG65929B1 (et)
BR (1) BR0110547A (et)
CA (1) CA2407965C (et)
CY (1) CY1109179T1 (et)
CZ (2) CZ2006291A3 (et)
DE (1) DE60138097D1 (et)
DK (1) DK1287035T3 (et)
EE (1) EE05548B1 (et)
ES (1) ES2323448T3 (et)
HU (2) HU230399B1 (et)
IL (1) IL152605A0 (et)
MX (1) MXPA02010823A (et)
NO (2) NO329843B1 (et)
NZ (1) NZ522881A (et)
PL (1) PL211733B1 (et)
PT (1) PT1287035E (et)
RU (1) RU2298013C2 (et)
TW (1) TWI318983B (et)
WO (1) WO2001083560A1 (et)
ZA (1) ZA200209230B (et)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CA2285040C (en) 1997-03-17 2009-01-27 Human Genome Sciences, Inc. Death domain containing receptor 5
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
EP1396500A4 (en) * 2001-05-18 2005-02-02 Kirin Brewery ANTI-TRAIL-R ANTIBODIES
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
AU2002307793B2 (en) 2001-10-19 2007-01-25 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
CN100506277C (zh) * 2001-11-01 2009-07-01 Uab研究基金会 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
NZ532881A (en) * 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
DE10210427A1 (de) * 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
US7772372B2 (en) 2002-07-04 2010-08-10 Patrys Limited Neoplasm specific antibodies and uses thereof
MXPA05005726A (es) 2002-11-27 2005-08-16 Irm Llc Metodos y composiciones para inducir apoptosis en celulas de cancer.
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
JP2007530588A (ja) * 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
CN100427505C (zh) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
ATE544781T1 (de) * 2004-12-13 2012-02-15 Cephalon Australia Vic Pty Ltd Osteoprotegerinvarianten-proteine
CA2595440A1 (en) 2005-02-02 2006-08-10 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5004154B2 (ja) * 2005-04-06 2012-08-22 一般財団法人化学及血清療法研究所 組換え抗ボツリヌス神経毒素抗体
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
UA97096C2 (ru) * 2005-08-31 2012-01-10 Емджен Інк. Выделенное антитело, которое специфически связывает рецептор-2 trail (tr-2)
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2553162T3 (es) 2006-05-16 2015-12-04 Daiichi Sankyo Company, Limited Método de producción de alta secreción de proteínas
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
KR100847010B1 (ko) * 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
KR100804126B1 (ko) 2007-02-09 2008-02-19 아주대학교산학협력단 종양 괴사 인자―관련 세포사멸―유도 리간드의 수용체에특이적으로 결합하는 1가의 인간 단일클론 항체 및 그의항원결합 단편
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
JPWO2009020093A1 (ja) * 2007-08-09 2010-11-04 第一三共株式会社 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
JP5288379B2 (ja) 2007-10-31 2013-09-11 独立行政法人産業技術総合研究所 タンパク質の高分泌生産方法
WO2010047509A2 (ko) * 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CA2775350A1 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
US9068019B2 (en) 2009-10-19 2015-06-30 Hanall Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
CN102666588A (zh) 2009-11-05 2012-09-12 Uab研究基金会 治疗基底细胞样基因型癌症
WO2011084623A1 (en) 2009-12-16 2011-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
PL2636736T3 (pl) * 2010-10-29 2016-09-30 Nowe przeciwciało anty-dr5
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
JP2014513128A (ja) * 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド 血管破壊剤とその使用
CN104507969A (zh) 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 抗siglec-15抗体
WO2014018625A1 (en) * 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CN103074425B (zh) * 2012-12-29 2014-01-01 深圳市第三人民医院 Cd263基因的用途
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN104710533A (zh) * 2013-12-12 2015-06-17 中国科学院深圳先进技术研究院 sDR5-Fc融合蛋白及其用途
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
WO2016122702A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
CN109195626B (zh) 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
CA3007031A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
CN106924735A (zh) * 2015-12-29 2017-07-07 上海交通大学医学院附属瑞金医院 多巴胺1类受体激动剂在制备肿瘤治疗药物中的用途
WO2017139485A1 (en) 2016-02-09 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
KR102812377B1 (ko) 2016-03-01 2025-05-23 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
US20200247897A1 (en) 2017-06-07 2020-08-06 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
KR101951025B1 (ko) 2017-08-17 2019-02-21 서울대학교산학협력단 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
TWI826393B (zh) * 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
WO2019100193A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
WO2019100194A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
CN108251443A (zh) * 2018-01-23 2018-07-06 深圳市人民医院 一种tnfrsf10c重组质粒、制备方法及其应用
WO2019173499A1 (en) 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN113226472B (zh) 2018-12-17 2025-01-28 雷维托普有限公司 双免疫细胞衔接物
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
EP1862548A1 (en) * 1997-01-28 2007-12-05 Human Genome Sciences, Inc. Death domain containing receptor 4 (DR4 : death receptor 4), member of the TNF-receptor superfamily and binding to trail (APO2-L)
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
CA2285040C (en) 1997-03-17 2009-01-27 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
AU734758B2 (en) 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
EP1007562A4 (en) 1997-04-16 2000-09-27 Millennium Pharm Inc TANGO-63d AND TANGO-63e PROTEINS RELATED TO THE TUMOR NECROSIS FACTOR RECEPTOR
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1860187B1 (en) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999003992A1 (en) 1997-07-15 1999-01-28 Immunex Corporation Trail receptor
WO1999007861A1 (en) 1997-08-06 1999-02-18 Laboratório Medinfar-Produtos Farmacêuticos, Lda. DNA INTEGRATION INTO 'MYCOBACTERIUM spp.' GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
ATE233887T1 (de) * 1997-08-13 2003-03-15 Sortech Ag Sorptionsspeicher, anordnung und verfahren zur speicherung von wärme
WO1999009165A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EP1012282B1 (en) 1997-09-12 2007-04-18 Biogen Idec MA Inc. Cysteine rich receptors-train
US7105640B2 (en) * 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
ATE517125T1 (de) 1998-01-26 2011-08-15 Genentech Inc ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
US20040120947A1 (en) 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
WO2000061757A1 (en) * 1999-04-12 2000-10-19 Genentech, Inc. Tumor necrosis factor homologs and nucleic acids encoding the same
CA2369371A1 (en) 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
AU4984300A (en) 1999-05-06 2000-11-21 Vishva M Dixit Death domain containing receptor 4
AU781952B2 (en) 1999-05-28 2005-06-23 Genentech Inc. DR4 antibodies and uses thereof
CA2375149A1 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP1226161A2 (en) 1999-09-15 2002-07-31 Genentech, Inc. Apo-2 receptor antibodies
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2426710A1 (en) 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6965023B2 (en) * 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
ATE433996T1 (de) 2001-07-03 2009-07-15 Genentech Inc Humane dr4-antikörper und deren anwendungen
CN100506277C (zh) 2001-11-01 2009-07-01 Uab研究基金会 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.

Also Published As

Publication number Publication date
EP1287035A4 (en) 2004-09-29
NO20025253L (no) 2002-12-18
KR20030055177A (ko) 2003-07-02
CZ306996B6 (cs) 2017-11-01
CY1109179T1 (el) 2014-07-02
US20110008324A1 (en) 2011-01-13
HUP0400951A2 (hu) 2004-07-28
NO338228B1 (no) 2016-08-08
CZ2006291A3 (cs) 2017-11-01
CZ304614B6 (cs) 2014-08-06
US20120076792A1 (en) 2012-03-29
JP4156238B2 (ja) 2008-09-24
EP2368910B1 (en) 2016-02-10
MXPA02010823A (es) 2004-05-05
HU230399B1 (hu) 2016-04-28
HU229417B1 (hu) 2013-12-30
HK1162524A1 (en) 2012-08-31
DK1287035T3 (da) 2009-06-15
US8329180B2 (en) 2012-12-11
KR20060092292A (ko) 2006-08-22
CN100497388C (zh) 2009-06-10
CN101585881B (zh) 2014-11-26
JP2007091749A (ja) 2007-04-12
ATE426615T1 (de) 2009-04-15
US20130243780A1 (en) 2013-09-19
PL211733B1 (pl) 2012-06-29
BR0110547A (pt) 2004-06-22
KR100817967B1 (ko) 2008-03-31
BG65929B1 (bg) 2010-05-31
CN101585881A (zh) 2009-11-25
JP2004502409A (ja) 2004-01-29
EP1287035A1 (en) 2003-03-05
DE60138097D1 (de) 2009-05-07
US8715668B2 (en) 2014-05-06
TWI318983B (en) 2010-01-01
BG109275A (en) 2006-10-31
RU2002132255A (ru) 2005-01-20
NO20054145L (no) 2002-12-18
HK1126506A1 (en) 2009-09-04
EP2065401A2 (en) 2009-06-03
AU5936601A (en) 2001-11-12
JP3892466B2 (ja) 2007-03-14
NO20025253D0 (no) 2002-11-01
HK1050372A1 (en) 2003-06-20
EP1287035B1 (en) 2009-03-25
EP2065401B1 (en) 2016-08-10
ES2323448T3 (es) 2009-07-16
JP4575975B2 (ja) 2010-11-04
CA2407965C (en) 2014-10-14
CN1440424A (zh) 2003-09-03
RU2298013C2 (ru) 2007-04-27
US7244429B2 (en) 2007-07-17
EP2065400A2 (en) 2009-06-03
EP2065400A3 (en) 2009-07-22
US20140308288A1 (en) 2014-10-16
PT1287035E (pt) 2009-06-30
PL366195A1 (en) 2005-01-24
US7790165B2 (en) 2010-09-07
EP2065400B1 (en) 2014-11-05
BG107275A (bg) 2004-09-30
HUP0400951A3 (en) 2012-09-28
NO329843B1 (no) 2011-01-10
JP2005232187A (ja) 2005-09-02
HU0500800D0 (en) 2005-10-28
IL152605A0 (en) 2003-06-24
AU2001259366B2 (en) 2005-09-08
BG66153B1 (bg) 2011-08-31
EP2065401A3 (en) 2009-07-22
US20070298039A1 (en) 2007-12-27
JP2009005707A (ja) 2009-01-15
US9700618B2 (en) 2017-07-11
CZ20023917A3 (cs) 2003-05-14
NZ522881A (en) 2005-05-27
EP2368910A1 (en) 2011-09-28
US8067001B2 (en) 2011-11-29
US20030190687A1 (en) 2003-10-09
ZA200209230B (en) 2004-03-16
WO2001083560A1 (en) 2001-11-08
EE200200621A (et) 2004-06-15
CA2407965A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
EE05548B1 (et) Kasvaja nekroosifaktori sarnase apoptoosi indutseeriva ligandi retseptori suhtes selektiivne antikeha ja selle kasutamine
AU2018264321A1 (en) Bispecific recombinant protein and use thereof
WO2004020404A3 (en) Modified transferin-antibody fusion proteins
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
MXPA04005266A (es) Inmunocitocinas con selectividad modulada.
EP2338915A3 (en) Anti-VEGF antibodies
EP1325932A3 (en) Anti-vegf antibodies
AU4639396A (en) Cytokine designated lerk-7
WO2004020405A3 (en) Modified transferrin fusion proteins
PL331240A1 (en) Cut off soluble tumour necrosis factor receptors of i and ii type
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2003055908A3 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
NZ592545A (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
AU2003270010A1 (en) Transferrin fusion protein libraries
WO2023114515A3 (en) Anti-pilra antibodies, uses thereof, and related methods and reagents
WO2005080426A3 (en) Protein ligands for nkg2d and ul16 receptors and uses thereof
WO2003056340A3 (en) Fadd proteins, phosphorylated p38-mapk and fasl as tumour markers
AU2232297A (en) Gene that imparts selective proliferative activity
WO2002006340A3 (en) Tetraspan protein and uses thereof
WO2002020567A3 (en) Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein